难治性心绞痛的管理:最新进展
综述指出,尽管使用抗心绞痛药物和/或血运重建,仍有2%至24%的冠心病患者存在每日或每周心绞痛。难治性心绞痛定义为持续超过3个月、由可逆性缺血引起、无法通过二线/三线药物、搭桥或支架控制的症状。治疗重点在于改善生活质量,综述讨论了常规药物、高级血运重建策略及2019 ESC指南推荐。
要点
- 难治性心绞痛定义为持续>3个月的可逆性缺血症状,优化药物和血运重建后仍无法控制。
- 患病率在冠心病患者中为2%至24%,治疗主要目标是改善生活质量。
- 综述涵盖指南导向药物组合、剂量及高级血运重建策略和2019 ESC指南推荐。
核心结论
- 难治性心绞痛的治疗对改善患者生活质量很重要,尽管预后获益不确定。
研究设计与样本
- 综述,聚焦难治性心绞痛的常规药物治疗、高级和新型血运重建策略及当前血管生成和干细胞疗法的潜在临床应用。
主要发现
- 尽管使用抗心绞痛药物和/或PCI或CABG,仍有2%至24%的冠心病患者有每日或每周心绞痛。
- 难治性心绞痛指持续>3个月的症状,由可逆性缺血引起,无法通过二线/三线药物、搭桥或支架控制。
关键数值与推荐
- 难治性心绞痛定义:持续>3个月的可逆性缺血症状,无法通过升级药物治疗(使用二线和三线药物)、搭桥或支架控制。
- 综述讨论了2019 ESC慢性冠脉综合征诊断和管理指南的推荐。
临床怎么用
- 临床中应识别符合难治性心绞痛定义的患者,并考虑指南导向的药物组合和剂量。
- 可评估高级血运重建策略(如慢性完全闭塞PCI、经心肌激光血运重建等)和神经调节等选项。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite the use of anti-anginal drugs and/or percutaneous coronary interventions (PCI) or coronary artery bypass grafting, the proportion of patients with coronary artery disease who have daily or weekly angina ranges from 2% to 24%. Refractory angina refers to long-lasting symptoms (for >3 months) due to established reversible ischaemia, which cannot be controlled by escalating medical therapy with the use of 2nd- and 3rd-line pharmacological agents, bypass grafting, or stenting. While there is uncertain prognostic benefit, the treatment of refractory angina is important to improve the quality of life of the patients affected. This review focuses on conventional pharmacological approaches to treating refractory angina, including guideline directed drug combination and dosages. The symptomatic and prognostic impact of advanced and novel revascularization strategies such as chronic total occlusion PCI, transmyocardial laser revascularization, coronary sinus occlusion, radiation therapy for recurrent restenosis, and spinal cord stimulation are also covered and recommendations of the 2019 ESC Guidelines on the Diagnosis and Management of Chronic Coronary Syndromes discussed. Finally, the potential clinical use of current angiogenetic and stem cell therapies in reducing ischaemia and/or pain is evaluated.
引用
- Davies A, Fox K, Galassi AR, et al. Management of refractory angina: an update. Eur Heart J. 2021. PMID: 33367764. doi:10.1093/eurheartj/ehaa820
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。